Genetically modified cells expressing a TGFbeta inhibitor, the cells being lung cancer cells
AssigneeNovaRx
InventorHabib Fakhrai
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions comprising a therapeutically effective amount of genetically modified cells containing a genetic construct expressing a TGFβ inhibitor effective to reduce expression of TGFβ, where the genetically modified cells are non-small cell lung cancer (NSCLC) cells or small cell lung cancer (SCLC) cells, and related methods.
Claims36
A composition comprising a therapeutically effective amount of genetically modified cells containing a genetic construct expressing a TGFβ inhibitor effective to reduce expression of TGFβ, wherein said genetically modified cells are lung cancer cells.
A method for prolonging survival of a subject having a lung cancer comprising the step of administering to said subject a composition comprising a therapeutically effective amount of genetically modified cells containing a genetic construct expressing a TGFβ inhibitor effective to reduce expression of TGFβ, wherein said genetically modified cells are lung cancer cells.
Dependencies are inferred from the claim text.